{"meshTags":["Angiogenesis Inhibitors","Antibodies, Monoclonal, Humanized","Bevacizumab","Drug Substitution","Humans","Ranibizumab","Receptors, Vascular Endothelial Growth Factor","Recombinant Fusion Proteins","Vascular Endothelial Growth Factor A","Wet Macular Degeneration"],"meshMinor":["Angiogenesis Inhibitors","Antibodies, Monoclonal, Humanized","Bevacizumab","Drug Substitution","Humans","Ranibizumab","Receptors, Vascular Endothelial Growth Factor","Recombinant Fusion Proteins","Vascular Endothelial Growth Factor A","Wet Macular Degeneration"],"genes":["anti-VEGF"],"publicationTypes":["Journal Article"],"title":"Current concepts in managing wet AMD suboptimally responsive to anti-VEGF therapy.","pubmedId":"23676221"}